Tower Research Capital (TRC)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,672
| Closed | -$31K | – | 6345 |
|
|
2023
Q3 | $31K | Sell |
1,672
-11,040
| -87% | -$125K | ﹤0.01% | 2994 |
|
|
2023
Q2 | $141K | Buy |
12,712
+2,739
| +27% | +$38.2K | ﹤0.01% | 1802 |
|
|
2023
Q1 | $134K | Buy |
9,973
+97
| +1% | +$1.68K | ﹤0.01% | 1623 |
|
|
2022
Q4 | $122K | Sell |
9,876
-27,496
| -74% | -$389K | 0.01% | 1680 |
|
|
2022
Q3 | $521K | Buy |
37,372
+28,953
| +344% | +$466K | 0.01% | 1108 |
|
|
2022
Q2 | $116K | Buy |
8,419
+4,457
| +112% | +$71.4K | ﹤0.01% | 2178 |
|
|
2022
Q1 | $64K | Sell |
3,962
-3,576
| -47% | -$56K | ﹤0.01% | 2543 |
|
|
2021
Q4 | $123K | Sell |
7,538
-8,535
| -53% | -$144K | ﹤0.01% | 2094 |
|
|
2021
Q3 | $239K | Buy |
16,073
+13,361
| +493% | +$214K | 0.01% | 1645 |
|
|
2021
Q2 | $54K | Buy |
2,712
+461
| +20% | +$9.14K | ﹤0.01% | 2976 |
|
|
2021
Q1 | $52K | Sell |
2,251
-7,561
| -77% | -$211K | ﹤0.01% | 3097 |
|
|
2020
Q4 | $242K | Buy |
9,812
+7,794
| +386% | +$258K | 0.01% | 1573 |
|
|
2020
Q3 | $84K | Sell |
2,018
-1,938
| -49% | -$89K | ﹤0.01% | 3284 |
|
|
2020
Q2 | $189K | Buy |
+3,956
| New | +$306K | 0.01% | 1836 |
|
|
2019
Q4 | – | Sell |
-550
| Closed | -$36K | – | 4594 |
|
|
2019
Q3 | $36K | Buy |
+550
| New | +$36.9K | ﹤0.01% | 2032 |
|
|
2019
Q2 | – | Sell |
-162
| Closed | -$18K | – | 4480 |
|
|
2019
Q1 | $18K | Sell |
162
-97
| -37% | -$10.6K | ﹤0.01% | 2340 |
|
|
2018
Q4 | $26K | Buy |
259
+160
| +162% | +$16.6K | ﹤0.01% | 1750 |
|
|
2018
Q3 | $13K | Buy |
+99
| New | +$10.5K | ﹤0.01% | 2620 |
|
|
2018
Q2 | – | Sell |
-1,916
| Closed | -$118K | – | 4188 |
|
|
2018
Q1 | $118K | Buy |
1,916
+880
| +85% | +$53K | 0.01% | 1160 |
|
|
2017
Q4 | $61K | Buy |
1,036
+258
| +33% | +$16.3K | 0.01% | 1186 |
|
|
2017
Q3 | $45K | Buy |
778
+650
| +508% | +$70K | ﹤0.01% | 2065 |
|
|
2017
Q2 | $15K | Buy |
128
+86
| +205% | +$9.96K | ﹤0.01% | 1383 |
|
|
2017
Q1 | $5K | Sell |
42
-169
| -80% | -$19.7K | ﹤0.01% | 2245 |
|
|
2016
Q4 | $23K | Buy |
211
+155
| +277% | +$18.5K | ﹤0.01% | 2027 |
|
|
2016
Q3 | $9K | Sell |
56
-85
| -60% | -$13.4K | ﹤0.01% | 2166 |
|
|
2016
Q2 | $20K | Sell |
141
-705
| -83% | -$103K | ﹤0.01% | 2246 |
|
|
2016
Q1 | $109K | Buy |
+846
| New | +$99.9K | 0.02% | 477 |
|
|
2015
Q3 | – | Sell |
-52
| Closed | -$13K | – | 4981 |
|
|
2015
Q2 | $13K | Buy |
+52
| New | +$13.8K | ﹤0.01% | 2486 |
|
|
2014
Q4 | – | Sell |
-7
| Closed | -$2K | – | 4856 |
|
|
2014
Q3 | $2K | Buy |
+7
| New | +$1.78K | ﹤0.01% | 3901 |
|
|
2014
Q1 | – | Sell |
-1,146
| Closed | -$78K | – | 5062 |
|
|
2013
Q4 | $78K | Buy |
1,146
+785
| +217% | +$45.4K | 0.01% | 1006 |
|
|
2013
Q3 | $25K | Sell |
361
-161
| -31% | -$7.95K | ﹤0.01% | 2519 |
|
|
2013
Q2 | $23K | Buy |
+522
| New | +$17.8K | ﹤0.01% | 1583 |
|
Tower Research Capital (TRC)'s ICPT Position: Q4 2023 in Review
Tower Research Capital (TRC) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 1,672 shares — an estimated $31K sold.
Tower Research Capital (TRC) first reported a position in ICPT in Q2 2013 and held it in 32 quarters. The position peaked at $521K in Q3 2022. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Tower Research Capital (TRC) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,672 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $31K.
- Tower Research Capital (TRC) first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
- Tower Research Capital (TRC)'s Intercept Pharmaceuticals, Inc. position peaked at $521K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.